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Introduction: Osteomyelitis is a destructive inflammatory condition of the bone that is 
usually caused by a wide range of microorganisms especially Staphylococcus aureus. 
Considering the downsides of systemic antibiotic therapies as well as conventional local 
drug delivery systems such as using polymethylmethacrylate, this study  aimed to 
develop, characterize and optimize vancomycin hydrochloride loaded multivesicular 
liposomes (MVLs) as a proper therapeutic option for the treatment of osteomyelitis.  
Methods and Results: A 23 full factorial design technique was applied to determine the 
effects of three variables (lipid to drug ratio, triolein content and cholesterol to 
phospholipid ratio) on the encapsulation efficiency and release profile of vancomycin 
hydrochloride loaded MVLs to optimize the final formulation. Further characterization 
was performed on the optimized formula by evaluating the morphology, size and storage 
stability. The average drug encapsulation efficiency and the mean diameter of the 
optimized formulation was 54.7 ± 0.3% and 9.019 ± 0.26 µm, respectively with a span 
value of 0.188. Additionally, the spherical and multivesicular nature of MVLs was 
visible using optical microscopy (x400). The optimized formula showed an in vitro 
sustained release characteristic with proper stability and insignificant change in size, 
morphology and EE% for 30 days at 4°C. 
Conclusion: This study suggests that vancomycin hydrochloride loaded MVLs might 
have the potential to be used in the treatment of chronic osteomyelitis as a biocompatible 
drug carrier with a high antibiotic entrapment capacity as well as controlled drug release. 
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Osteomyelitis is a destructive inflammatory condition of 
the bone that is usually caused by an invasive infection 
and is identified by pathological changes in bone 
regeneration. Nowadays, the incidence of this disease is 
increasing and can involve all ages and each bone, and 
become a chronic disease and cause persistent morbidity 
[1]. Treatment is especially challenging when a complex 
multidrug-resistant bacterial biofilm is developed. 
Bacteria in the biofilm remain in a low metabolic stage 
and could cause persistent infection due to increased 
resistance to antibiotics. Furthermore, some host factors, 
make treatment of the disease even more challenging 
such as the formation of a "sequestrum" at the site of 
infection, which prevents penetration of antimicrobial 
agents into the infected site. Although this infection can 
be caused by a wide range of microorganisms, 
2 M. Vatankhah et al. International Pharmacy Acta, 2021;4(1):e6 
 This open-access article is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0). 
Staphylococcus aureus and Staphylococcus epidermidis 
are the most common causes of the disease respectively, 
which are responsible for more than 50% of cases of 
osteomyelitis [2]. 
The conventional treatment methods of osteomyelitis 
consist of the removal of necrotic tissue, rinsing the 
infected site with a proper antiseptic, and administrating 
a high dose of prolonged parenteral (at least 4 to 8 
weeks) antibiotic treatment. These systemic therapeutic 
methods have some serious disadvantages such as 
nephrotoxicity, ototoxicity, and gastrointestinal side 
effects, as well as bacterial resistance in case of 
insufficient doses of antibiotics or incomplete treatment 
[3,4]. 
Although oral antibiotics administration has some 
upsides including ease of use, cost decrease, and shorter 
period of hospitalization, it also has some downsides 
such as the unpredictable therapeutic efficiency, 
limitation of drug type and prescribed dosage, treatment 




Given all these limitations and deficiencies, local 
antibiotic therapy offers several advantages such as 
providing high local concentration with lower systemic 
effect over parenteral and oral drug administration [2,5]. 
In recent years, non-biodegradable drug carriers named 
PMMA (polymethylmethacrylate) have been fostered. 
Commercial PMMAs are available in the form of beads 
(Septopal ®) and Cement.
2
 Although usage of PMMAs 
has rectified the drawbacks of intravenous antibiotics to 
some extent, still it has some important downsides which 
cause several issues for patients. Some of these 
drawbacks are mentioned below:  
1. Since PMMAs are non-biodegradable, a second 
surgery to remove the carrier is inevitable which imposes 
more pain, cost and longer treatment duration [2,4,6] 
2. Many studies declare that the use of PMMAs could 
delay the bone restoration process [4]. 
3. In the course of the polymerization process, due to the 
liberation of excessive amounts of heat, antibiotics may 
be neutralized [2]. 
4. In some cases, either antibiotic release is not entirely 
accomplished or is completed very slowly, the use of 
PMMAs could cause antibiotic resistance
 
[4]. 
5. PMMAs placement and removal processes increase 
the risk of secondary infection considerably
 
[7]. 




Based on the mentioned issues, in recent years, the 
design of biodegradable local drug delivery systems is a 
prevalent case study among many researchers. Some 
studies in the biomaterial field, have performed 
biodegradable scaffolds designs to find alternatives for 
current PMMAs. Bioceramics, bioactive glasses, 
polymer scaffolds and composites are among these 
materials which have their own advantages and 
drawbacks. The common upside of these scaffolds 
compared to PMMAs is absence of the second surgery 
for removal of the carrier, but the main disadvantage of 
these methods is still the necessity of the primary 
surgery for placement of these carriers
 
[4]. 
MVLs, also known as Depofoams, are lipid-based and 
sustained-release carriers that contain multiple 
nonconcentric aqueous chambers. MVLs have many 
advantages over other classic types of liposomes namely 
having a significantly slower drug release rate and higher 
storage stability. Compared to polymeric encapsulation 
systems, Depofoams are both biodegradable and 
biocompatible as they are derived from natural lipids. 
The spacious internal aquatic chambers in MVLs allow a 
highly efficient loading of hydrophilic drugs along with 
a controlled and prolonged release profile. Their close-
packed nonconcentric structure allows them to rearrange 
their vesicles internally and also is responsible for MVLs 
stability and drug sustainability [10,11,12]. 
Since the 1950s ,vancomycin hydrochloride (Van. H) 
has been used against gram positive bacteria such as 
Staphylococcus aureus. Nowadays, this glycopeptide 
antibiotic is still widely used as one of the most effective 
treatment options for bone infections. S. aureus is one of 
the most pathogenic origin of osteomyelitis and Van. H 
is one of the few available antibiotics to treat infections 
caused by S. aureus and methicillin-resistant 
Staphylococcus aureus (MRSA) [2,8,9]. 
Considering the above-mentioned advantages of local 
delivery of antibiotics and effectiveness of Van. H for 
treatment of osteomyelitis, as well as benefits of MVLs 
as a biocompatible carrier with a high ability of 
sustained drug release, this study aimed to develop and 
characterize Van. H loaded MVLs as a proper 
therapeutic option for treatment of osteomyelitis. A 2
3
 
full factorial design technique was applied to determine 
the effects of three variables (lipid to drug ratio (L/D), 
triolein content (To%) and cholesterol to phospholipid 
ratio (Chol/PL)) on the encapsulation efficiency and 
release profile of the MVLs to optimize the final 
formulation. 
 
2. Materials & Methods 
 
2.1. Materials  
 
Van.H was purchased from Jaber Ebne Hayyan 
Pharmaceutical Co. (Tehran, IRAN). Amphipathic lipid, 
purified egg phosphatidylcholine r (EPC) was obtained 
from Lipoid GmbH (Ludwigshafen, Germany). 
Negatively charged lipid (dicetyl phosphate or DCP), 
cholesterol, neutral lipid (triolein) and free base L-
Lysine were purchased from Sigma–Aldrich (USA). 
Chloroform and methanol were supplied by Merck 
(Germany). Dextrose 5% was obtained from Iranian 
parenteral and pharmaceutical Co. (Tehran, IRAN). 
Multivesicular liposomes for the sustained delivery of vancomycin hydrochloride. 3  
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2.2. Preparation of multivesicular liposomes 
 
Van H-MVL was prepared by double emulsion (w/o/w) 
method described in previous reports [13,14] Figure 1 
demonstrates the schematics process of MVLs 
preparation. First, a water in oil emulsion was prepared 
by mixing 1 ml aqueous phase containing 6 mg/ml Van. 
H and 5% Dextrose, and 1 ml oil phase containing 
chloroform solution with amphipathic lipid (Egg PC), 
cholesterol, triolein and DCP using 15 min vortex 
(12,000 rpm). Subsequently, the second aqueous solution 
containing 40 mmol/L lysine was mixed with the 
primary emulsion for 1 min (10,000 rpm). Then the 
chloroform was removed by using a rotary evaporation. 
The resulting MVLs were isolated by centrifugation at 
7500 rpm and washed twice with normal saline 0.9% to 
remove unentrapped Van. H, then resuspended in a L-




Figure 1. Schematic presentation of the preparation process of Van. H 
loaded MVLs. 
 
2.3. Effect of variables 
 
A two-level factorial design using Design-Expert® 
software (Version 12, Stat-Ease Inc., Minneapolis, MN, 
USA) was applied to study the effects of three different 
variables including L/D, To% and Chol/PL on the 
encapsulation efficiency and release profile. Each 
independent variable was set at three (low, midpoint and 
high) levels (Table 1). The values of each variable was 
considered according to preliminary studies. The 
Encapsulation efficiency, percentage of drug released 
after 24 h (DR24h%) and percentage of drug released 
after 48 h (DR48h%) were chosen to be dependent 
variables. The effects of the three independent variables 
were studied through 12 experiments. Besides, three 
center points were added to estimate the experimental 
errors. All batches were prepared randomly in duplicate 
pursuant to run orders and analyzed triplicate for 
entrapment efficiency (EE) and percent drug release. 
Each response coefficient and significance of the effects 
of variables were investigated using ANOVA, Pareto 
chart and Perturbation plot. Two-dimensional contour 
plots and three-dimensional response surface plots were 
used to study the combined effects of independent 
variables on the selected response. Statistical 
comparisons were evaluated by ANOVA with a 
significance level of P < 0.05. 
 
Table 1. Investigated independent formulation variables and their 






Low (-1) Midpoint (0) High (+1) 
A: Chol/ PL molar ratio 1.0 2.0 3.0 
B: L/D molar ratio 20 30 40 
C: To% 10 15 20 
Abbreviations: Chol/PL, cholesterol to phospholipid ratio;  
L/D, lipid to drug ratio, To%: triolein percentage. 
 
2.4. MVL characterization 
 
2.4.1. MVL morphology, size and size distribution 
 
The morphology of vesicles was determined using an 
inverted microscope (×400) connected to a digital 
camera (Optika, Italy). Particle size and size distribution 
were measured by a Mastersizer 2000 (Malvern 
Instruments, UK). 
 
2.4.2. MVL Encapsulation Efficiency (EE%) 
 
To determine Van.H content in the MVL formulations, a 
sample of each formulation (100 μl) was lysed with 
methanol (900 μl) and further vortexed for 5 min.  
The UV spectrophotometry (UV-mini 1240, Shimadzu, 
Japan) method at 281 nm was used for quantitative 
estimation of Van H entrapped in MVLs. All the 
measurements were repeated three times and EE% was 
calculated using under-mentioned formula [15]: 
 
                            
                   
                        
     
 
2.4.3. In vitro release 
 
The in vitro release study of Van. H-MVL was 
determined at 37 °C using dynamic dialysis technique. 
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All formulations considering their specific encapsulation 
efficiency were used for this analysis. Briefly, 500 µl of 
each formulation was kept in a dialysis bag with a 
molecular weight cut-off of 14 kDa, and the system was 
immersed in 15 ml of pH 7.4 phosphate buffer saline 
(PBS) solution. The medium was shaken at 37±0.5 °C 
and 50 rpm. At regular time intervals (1, 2, 4, 8, 12, and 
then every 24 h), 500 µl of the release medium was taken 
out and was replaced with same volume of fresh medium 
in order to maintain the sink condition. Samples were 
collected for up to 7 days. The percentage of drug 
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released was calculated using the UV spectrophotometry 
according to the standard curve of Van. H at λmax=281 nm. 
The mean calculated values were determined from 3 
replicates. 
 
2.4.4. Storage Stability 
 
The optimized Van H-MVLs were stored at 4°C for 30 
days. The stability of MVLs was evaluated by measuring 
some stability indicators including size, morphology, and 
EE% at the determined time points. 
 
2.5. Statistical analysis 
 
All tests were performed in triplicate and results were 
represented as mean ± standard deviation (SD). 
Statistical comparisons were carried out using ANOVA 
and differences were considered statistically significant 
for p < 0.05. 
 
3. Results and Discussion 
 
3.1. Analysis of 23 factorial design 
 
Experimental design has been recognized as a helpful 
and practical tool for formulation development and 
optimization as it represents an efficient approach to 
evaluate all formulation factors systematically in a 
timely manner [16].
 
As lipid concentration and composition could have a 
direct effect on MVL efficacy (EE% and release rate), 
we investigated different properties of the MVLs 
prepared at varying Chol/PL molar ratios, L/D molar 
ratios and To%. The ranges of these parameters were 
firstly determined based on preformulating studies. The 
effect of these three variables on three response 
parameters including EE%, 24 hours release rate 
(DR24h%) and 48 hours release rate (DR48h%) was 
designed via a 2
3
 full factorial design (Table 2). 
 












EE%* DR24h% DR48h% 
1 2.00 30.00 15.00 37.2 ± 0.3 72.9 ± 0.7 86.2 ± 0.6 
2 1.00 40.00 20.00 30.2 ± 0.2 53.3 ± 0.6 68.4 ± 0.3 
3 2.00 30.00 15.00 36.8 ± 0.5 71.2 ± 0.3 84.9 ± 0.1 
4 3.00 40.00 20.00 31.87 ± 0.3 67.8 ± 0.5 79.3 ± 0.6 
5 3.00 20.00 20.00 30.16 ± 0.4 84.5 ± 0.8 94.6 ± 0.2 
6 2.00 30.00 15.00 37.01 ± 0.1 73.8 ± 0.5 87.0 ± 0.4 
7 1.00 40.00 10.00 47.65 ± 0.5 66.7 ± 0.5 81.3 ± 0.8 
8 3.00 20.00 10.00 40.32 ± 0.7 77.6 ± 0.6 92.6 ± 0.1 
9 3.00 40.00 10.00 54.7 ± 0.3 64.6 ± 0.8 79.6 ± 0.5 
10 2.00 30.00 15.00 36.65 ± 0.2 71.8 ± 0.2 84.2 ± 0.3 
11 1.00 20.00 20.00 24.87 ± 0.4 69.4 ± 0.4 82.2 ± 0.6 
12 1.00 20.00 10.00 39.18 ± 0.1 78.3 ± 0.6 91.6 ± 0.4 
*Abbreviations: Chol/Pl: Chol to phospholipid molar ratio, L/D: lipid to drug molar ratio, To: Triolein, EE: encapsulation efficiency 
 
 
Following the responses calculation (EE%, DR24h%, 
DR48h%), ANOVA test and Pareto charts were applied 
to examine the statistical significance of the parameters 
and the insignificant ones were excluded from the study 
(Figure 2). Through evaluation of the Pareto chart which 
represents the effects of variables by displaying two 
significance thresholds (t-value and Bonferroni limit). 
The effects situated above the Bonferroni line are 
indicated statistically significant, and those located 
between the Bonferroni and t-value limit lines are 
demonstrated to be possibly significant, while those 
under the t-value limit are statistically insignificant and 
should be eliminated from the analysis [17]. 
 
(a) 
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Figure 2. Pareto chart of the analyzed effects for (a) EE%, (b) 
DR24h% and (c) DR48h% 
 
3.2. Effects of variables on encapsulation efficiency: 
 
As seen in Table 2, MVLs were obtained with EE% in 
the range of 24.87% to 54.7%. To describe the effect of 
three formulation variables on EE%, multiple linear 
regression analysis (MLRA) was applied and the 
suggested polynomial model was then simplified by 
removing non-significant terms (P > 0.05). The obtained 
model is expressed as the following equation: 
 
1. Y1 (%EE) = + 36.28 + 0.9462 A + 3.59 B – 8.02 C + 
0.1425 AB –0.0775 AC –1.37875 BC–0.5963 ABC 
 
As mentioned earlier, the A, B, C, terms stand for the 
Chol/PL molar ratio, L/D molar ratio, and the To%, 
respectively. As shown in in the ANOVA analysis, the 
model is significant (F-value of 602.44 (P < 0.0001)) and 
there is only 0.01% chance that such a large F-value 
could arise due to noise. Besides, the lack of fit with the 
F-value of 9.08 (P-value of 0.0571) is statistically 
insignificant which means our model fits the actual 
response behavior well. Furthermore, the difference 
between the predicted R-squared (0.8624) and the 
adjusted R-squared (0.9974) is less than 0.2, indicating a 
reasonable agreement between the two values. Adequate 
Precision measures the signal to noise ratio and a ratio 
more than four is desirable. Consequently, our ratio of 
89.181 specifies an adequate signal and this model can 
be applied to navigate the design space. The Pareto plot 
(Fig 2.a) and the equation demonstrate that the factor C 
(To%) has a remarkable negative effect on the EE% with 
the F-value of 2449.80 (P < 0.0001) while there is a 
positive correlation between both A (Chol/PL) and B 
(L/D) variables and Van.H entrapment with F-value of 
170.73 (p=0.0002) and 492.86 (p < 0.0001), 
respectively. 
In the MVL structure, employing neutral lipids such as 
triolein is critical for the stabilizing of multivesicular 
liposomes structure [18]. The results of microscopic and 
NMR evaluations have shown that triolein, not only acts 
as a stabilizing agent and hydrophobic filler in the spaces 
between vesicles junctions, but also present in the 
encapsulated aqueous phase as dispersion of oil droplets 
[13]. 
According to previous reports, the optimal concentration 
of triolein has a profound effect on the percentage of EE 
[18]. Triolein, in a proper range, increase the stability of 
the MVL structure and therefore impose an additive 
effect on the EE. However, it would reduce the 
encapsulation efficiency in higher amounts. Given that 
the Van.H is a large hydrophilic molecule with a 
molecular weight of 1485.7 g/mol, [19] it is expected to 
be placed in the internal aqueous space of the liposome. 
It seems that using higher proportion of triolein, by 
occupying the internal aqueous space, limits the 
entrapment capacity of this large molecule and therefore 
has a reducing effect on EE%. 
A positive correlation was shown between Chol/PL ratio 
(A variable) and Van. H entrapment. The increase in 
EE% with increasing the Chol/PL ratio can be due to the 
reason: that increasing the cholesterol as a membrane 
fluidity buffer can lead to increased membrane stability, 
reduced drug leakage throughout the MVL preparation 
process and eventually enhancing EE%. 
The positive impact of L/D ratio (variable B) on the EE 
may be explained by the fact that due to the special 
structure of multivesicular liposomes, increasing the 
concentration of lipid can lead to growth in the number 
of vesicles per milliliter and subsequently the final 
volume for drug encapsulation per milliliter, and drug 





6 M. Vatankhah et al. International Pharmacy Acta, 2021;4(1):e6 
 This open-access article is distributed under the terms of the Creative Commons Attribution Non Commercial 4.0 License (CC BY-NC 4.0). 
The perturbation plot is a useful representative tool to 
compare the effects of all the factors at a particular point 
in the design space and helps to find factors that affect 
the response the most. The response is graphed by 
changing only one factor over its range. while other 
variables are maintained constant. The curvature or steep 
slope in this graph determines the response sensitivity to 
that parameter [21,22]. As demonstrated in Figure 3, a 
steep slope for factor C (To%) and a slight slope for 
factor A (Chol/PL) indicates that the To% is a significant 
factor for controlling the EE%. Given that the slope of 
the graph is negative for this factor, it has a remarkable 
decreasing effect on the selected response (EE%). 
The combined effects of independent variables on 
selected response were further studied by Response 
surface methodology including two-dimensional contour 
plots and three-dimensional response surface plots. 
These plots were drawn by maintaining one variable 
constant at the center point while changing the other two 
variables within the experimental range. The 3D 
response surface plots are very helpful for studying both 
the main and interaction effects of the independent 
factors. The 2D contour plots give visual clues on the 
values of the response in order to optimize the response 
function [23,24]. 
As illustrated in Figure 4 (a and b) by keeping the factor 
A constant at the highest value (Chol/PL=3), the 
combined effects of the other two factors on the response 
were investigated. The results showed that increasing the 
L/D ratio to its highest level (40) while reducing the 
To% to 10%, would cause the highest EE (50% and 
more). As shown in Figure 5 (a and b) by maintaining 
factor C constant at the lowest value, the maximum 
value of EE is obtained by increasing the other two 
factors. According to Figure 6 (a and b), by keeping the 
factor B constant at the value of 40, EE% will increase 
as factor C decreases and factor A increases. The 
findings of 3D response surface plots and contour plots 




Figure 3. Perturbation plot displaying the effect of three variables on 





Figure 4. Two-dimensional contour plots(a) and three-dimensional response surface plots (b) showing the combined effects of factor B (L/D) and 
factor C (To%) on EE%. 
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Figure 5. Two-dimensional contour plots(a) and three-dimensional response surface plots (b) showing the combined effects of factor A (Chol/PL) 




Figure 6. Two-dimensional contour plots (a) and three-dimensional response surface plots (b) showing the combined effects of factor A (Chol/PL) 
and factor C (To%) on EE%. 
 
3.3. Effects of variables on the drug release rate: 
 
MVL is differentiated from conventional liposomes 
(unilamellar and multilamellar liposomes) by its unique 
characteristic structure and composition [25]. MVLs are 
made up of several nonconcentric aqueous chambers and 
contain more than 90% of water, so they are a unique 
carrier system for hydrophilic drugs. One of the specific 
structural features of MVLs is the presence of a neutral 
lipid such as triolein, tricaprylene, trilaureine, 
tributyrine, etc in their structure which plays a 
significant role in stabilizing the membrane [25,26]. 
These features allow MVL to overcome the limitations 
of conventional liposomes such as low entrapment 
efficiency for water-soluble drugs and drug release after 
a single breach in the outer membrane. Very low 
aqueous entrapment is an important barrier to the use of 
conventional liposomes for hydrophilic drugs. Unlike 
conventional liposomes, a breach in the outer 
membranes of this system leads to the release of the 
encapsulated drug into the external medium, and the 
release of the drug from the internal vesicles leads to the 
redistribution of the drug inside the particle instead of 
releasing from the particle.  
As shown in Table 2, the percentage of drug released 
from the prepared formulations ranged between 53.35% 
to 84.51% over 24 hours and 68.41% to 94.64% for 48 
hours. Polynomial models between the dependent 
variables (DR24h% and DR48h%) and independent 
variables were fitted by applying multiple linear 
regression. For both DR24h% and DR48h % the 
predicted R
2
 is in a reasonable agreement with the 
adjusted R
2
 (0.8748 Vs. 0.9492 and 0.8704 Vs. 0.9388 
and respectively). As „adequate precision‟ ratio is greater 
than 4 for both responses, this model can be used to 
navigate the design space. Through the statistical 
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analysis for optimization of MVLs, the quadratic model 
was found significant (p < 0.05) for DR24h%(Y2) and 
DR48h%(Y3) of MVLs. The polynomial equations were 
created with significant factors which is expressed as 
follows: 
 
2. Y2 (DR24h%) = + 69.35 + 1.62 A – 7.09 B – 3.50 C – 
0.1781 AB + 2.09 AC –0.9087 BC 
 
3. Y3 (DR48h%) = + 82.94 + 1.37 A – 6.63 B – 4.05 C + 
1.54 AC –0.6575 BC 
 
As indicated by the equation and the Pareto plots (Fig 2 
b and c), the variable B (L/D ratio) as the most effective 
factor, exhibits a negative effect on the release rate 
which means increasing the B level leads to a decrease in 
the release rate. This observation is in agreement with 
the study of  Johenston et al., in which the half-times for 
doxorubicin release from large unilamellar vesicles 
(LUV) was increased more than 6-fold by increasing the 
D/L ratio from 0.05 (wt/wt) to 0.39 (wt/wt) [27]. The 
likely explanation is that, with an increase of lipid 
content, the number of MVL vesicles also increases, 
resulting in less drug being loaded in each vesicle and 
consequently the release rate decreases as each vesicle 
release its content independently of the others [20].
 
According to equations 2 and 3, factors C (To%) and A 
(Chol/PL) have a negative and a positive effect, 
respectively on both 24h and 48h release rate. All these 
findings are confirmed by perturbation plots which are 
shown in Figure 7. 
To further study the combined effects of independent 
variables on the release rate, contour plots (2D and 3D) 
were examined. As revealed in Figure 8 (a and b) and 
Figure 9 (a and b), by keeping the To% constant at its 
highest level, drug release rate over 24 and 48 h was 





Figure 7. Perturbation plot displaying the effect of three independent 
variables on the drug release rates after 24 hours (a) and 48 hours (b) 




Figure 8. Contour plots showing the combined effects of factor A (Chol/PL) and factor B (L/D) on DR24h%. (a): two dimensional and (b): three 
dimensional plots 
Multivesicular liposomes for the sustained delivery of vancomycin hydrochloride. 9  




Figure 9. Contour plots showing the combined effects of factor A (Chol/PL) and factor B (L/D) on DR48h%. (a): two dimensional and (b): three 
dimensional plots 
 
According to previous studies, trioline, a neutral lipid 
with a long chain of 18 carbons, plays an important role 
in the stability of the MVL‟s lipid membrane [28,29]. it 
is worth noting that the amount of triolein, like other 
structural components of the MVL, should be within an 
optimal range, otherwise the surplus of triolein can enter 
into the water phase in the form of small droplets, and 
change the acidity of the internal water phase. 
Accordingly, this process can accelerate the release rate 
by affecting the osmotic pressure in the internal aqueous 
phase [18].
 
As previously discussed, cholesterol plays an imperative 
role in liposome composition [18].
 
Due to the location of 
cholesterol across the phospholipid bilayer of the 
membrane, its impact on the release rate of hydrophobic 
and hydrophilic drugs in liposomes has always been 
discussed extensively. Based on a study by Briuglia et 
al., Increasing the percentage of Chol accelerates the 
release rate of hydrophilic drugs [30]. On the contrary, 
due to the location of the hydrophobic drugs which 
interact with the long chain of lipids, high percentage of 
cholesterol will cause a less drug entrapment and a lower 
release action since the steric hindrance. In fact, given 
the key role of cholesterol in regulating membrane 
fluidity, it seems that an extra amount of cholesterol may 
increase the rigidity of the membrane and cause the lipid 
membrane to be more fragile [18,30]. 
 
3.4. Selection of optimized formulation 
 
In order to estimate the optimization capability of the 
mathematical models generated by 2
3 
factorial design, a 
numerical optimization model was used. The optimized 
formula was made by adjusting the determined range for 
each factor and also minimizing and maximizing each 
response. The desired range for each factor, including 1< 
A (Chol/PL) < 3, 20 < L/D < 40 and 10 < C (To%) < 30 
was selected based on the values determined in the 
experiment design, the results, as well as the possibility 
of formula stability. Besides, to assess the proper range 
of responses, EE% and releases were set to the 
maximum and minimum levels respectively. Finally, the 
formula suggested by the software was evaluated for 
morphology, EE %, release rate, and stability. 
Various ratios of the independent variables for the 
optimum formulation were suggested by the software. 




Figure 10. Optimized solution designed by factorial design 
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Figure 11. Photomicrograph of (a)multilamellar vesicles (MLVs) and (b) optimized Van H-MVLs  through optical microscopy (×400) 
 
 As can be seen from this figure, the values selected as 
the optimal formula correspond to formula #9. Given 
that the optimal values include the maximum and 
minimum levels specified in the range of each factor, it 
was reasonable to check the effect of higher and lower 
values on the responses as well. Since an L / D ratio 
above 40 and Chol/PL above 3 are uneconomical and 
impractical, MVLs with triolein values of 5% and 7% 
were prepared and evaluated. Due to the important role 
of triolein in the structural stability of MVLs, especially 
at the junctions between vesicles, a decrease in the molar 
ratio of triolein less than 10% had a significant effect on 
the apparent stability of liposomes. Therefore, large 
multilamellar structures (MLVs) were observed in 
microscopic examinations rather than MVL structures 
(Figure 11 a). Consequently, formula # 9 with a lipid 
composition of EPC: CHOL: To: DCP (20.75:62.25:10:7 
mol ratio) was selected as the optimal formula. This 
formulation showed an appropriate controlled release 
profile and the highest encapsulation efficiency (Table 
2). Further characterization was performed by evaluating 
the morphology, size and storage stability of the 
optimized Van. H-MVLs. 
3.4.1.  Release profile of the optimized formulation: 
 
As shown in Figure 12, what was observed in the 
optimal formulation release profile includes an initial 
burst release followed by a short lag phase and then a 
secondary sustained release phase. According to a study 
by Manna et al., this three-phasic release profile is 
consistent with the features of MVL as a complex 
dosage carrier. The initial burst is probably due to the 
release of the free or rapidly dissolved drug from the 
MVL surface vesicles. Chemical (e.g., surfactants) or 
physical (e.g., mechanical shear) stressors can accelerate 
burst release through increasing surface erosion [31]. It 
is well known that the treatment of osteomyelitis as an 
infectious disease with the potential for biofilm 
formation requires fast initial release of antibiotics 
followed by a sustained one in order to entirely suppress 
the infection [32-34]. The lag phase is determined to 
have no significant release of the drug after an initial 
burst release and before the secondary release phase. 
This phase occurs due to the temporary discharge of the 
surface drug and the pursuant slow diffusion through the 
lipid barriers. It was believed that rearrangement of the 
10 µm 
10 µm 
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“honeycomb” vesicles played an important role in the 
“lag” phase. In our study, considering that EPC with a 
less rigid structure compared to the other phospholipids 
was used, vesicles rearrangement appears to occur 
rapidly and therefore the lag phase is short and 
imperceptible. Moreover, the secondary release phase 
was associated with continued MVL erosion through 
lipid hydrolysis and it should be noticed that the 
continuity and sustainability of the release depends on 
this stage [31]. 
In a study by Liu et al. on liposome-loaded vancomycin, 
nearly 80% of the drug was released within 12 hours 
[11]. In our study, in addition to a significant reduction 
in release rate compared to the same study in liposomes, 




Figure 12. In vitro release profile of free drug and Van H-MVLs in 
PBS (pH 7.4) (mean ±SD, n=3). 
 
3.4.2. Morphology and size of optimized formula 
 
As shown in Figure 11 b, using optical microscopy 
(x400), the spherical and multivesicular nature of MVLs 
was visible. This non-centric granular structure gives the 
MVLs a “honeycomb” appearance that distinguishes 
them from other liposomal structures. The particle size 
of optimized MVLs has also been identified by 
Mastersizer 2000. The profile showed a single peak with 
a mean diameter of 9.019 ± 0.26 µm, and the span of 




Figure 13. The particle size distribution of Van H-MVLs.  
3.4.3. Stability of the optimized formulation 
 
The physicochemical stability of the optimized 
formulation was studied by monitoring its EE%, size and 
morphological change for 30 days at 4°C. As indicated 
in Table 3, proper stability was found with insignificant 
change in size, morphology and EE%. 
 
Table 3. Stability of the optimized formulation after storage at 4°C for 
1 month 
Time (week) Size (µm) EE% 
0 9.01 ± 0.26 54.7 ± 0.6 
1 9.12 ± 0.17 53.62 ± 0.3 
2 9.08 ± 0.34 53.21 ± 0.4 
3 9.14 ± 0.12 54.00 ± 0.7 




In this study, vancomycin hydrochloride was 
successfully loaded in multivesicular liposomes by 
double emulsion method using two-level full factorial 
design. All prepared MVLs were thoroughly 
characterized. In microscopic examinations, MVLs with 
expected and distinguishable appearance from other 
common liposomes were observed. For the optimized 
formulation, the average drug encapsulation efficiency 
and the mean particle diameter were 54.7 ± 0.3% and 
9.019 ± 0.26 µm, respectively and the distribution was 
relatively homogenous. A sustained and slower drug 
release rate was shown compared to the free drug as well 
as previously reported Van. H loaded classic liposomes 
[11]. These findings suggest that Van H-MVLs might 
have the potential to be used in the local treatment of 
chronic osteomyelitis as a biocompatible drug carrier 
with a high antibiotic entrapment capacity as well as 
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